To investigate the feasibility, image quality, and clinical implications of an ultra-low-dose contrast injection computed tomography angiography (CTA) protocol in patients scheduled for transcatheter aortic valve implantation (TAVI).
Introduction
Transcatheter aortic valve implantation (TAVI) has emerged as the new standard of care for patients with symptomatic severe aortic valve stenosis who are deemed inoperable or of high surgical operative risk. 1 -4 Computed tomography angiography (CTA) enables precise aortic annulus sizing 5 and aorto-iliac artery evaluation, 6 playing a key role in support planning of the TAVI procedure for the appropriate vascular access strategy, prosthesis size, and preventing procedural complications. 7, 8 The main limitation of CTA in the elderly, high-risk TAVI population often suffering from chronic kidney disease is the large amount of iodinated contrast media (CM) needed to visualize the entire aorta and the ilio-femoral access, resulting in a consistent risk of acute kidney injury (AKI) (incidence varies from 4 to 41%). 9, 10 AKI is a serious and well-known complication of the use of CM that negatively influences the outcome of TAVI procedure, leading to dialysis, prolonged hospitalization, increased morbidity, and mortality. 11 -15 Consequently, a reduction of CM could represent a leading point in such a high-risk population. The purpose of this study was to evaluate the feasibility of an ultra-low-dose CM injection protocol for 64-slice CTA of patients scheduled for TAVI by considering intraluminal attenuation and image quality of both aortic annulus and aorto-iliac CTA images.
Secondary end points were to evaluate the dimensions of the aortic root and peripheral access, patient's eligibility for TAVI, and clinical outcomes. Mean estimated radiation dose was also assessed.
Methods

Patients population
Between March 2011 and February 2013, 237 consecutive patients referred for diagnostic work-up for TAVI were included in our TAVI database. Of these patients, 197 (83.1%) were eligible for preprocedural CTA. Reasons for CTA not being performed were previous severe adverse reactions to an iodinated contrast agent (n ¼ 3, 1.3%) and severely impaired renal function: estimated glomerular filtration rate (GFR) ,3 mL/min/1.73 m 2 (n ¼ 37, 15.6%). Of these 197 patients, 35 (17.8%) were excluded from the study because of their body mass index (BMI) of .29 kg/m 2 and underwent standard TAVI work-up (CTA examination with a fixed protocol of 12 mL of CM at 4.5 mL/s). Thus, a total of 162 patients with a BMI of ≤29 kg/m 2 , who had undergone 64-slice CTA with our BMI-adapted CM injection protocol, were included in the study. Heart rate, heart rate variability, and heart rhythm were recorded before and during CTA examination. No premedication with b-blockade was administered because of concerns regarding the patients' known severe aortic stenosis. Patients with an estimated GFR of between 30 and 60 mL/min/1.73 m 2 underwent pre-CTA hydration, as per routine institutional protocol. The hydration protocol typically used in our hospital consists of IV volume expansion with crystalloid (1.0 -1.5 mL/kg/h) for 3 -12 h before the examination and continued for 6 -24 h afterward. In addition, these patients received 1200 mg of N-acetylcysteine orally three times a day before and after CTA. All patients provided written informed consent for the procedure and complete clinical and imaging data collection in our prospective TAVI database.
CTA acquisition
All the scanning parameters are described in Table 1 . All CTA examinations were performed using a 64-slice CT system (LightSpeed VCT-XTE scanner, GE-Healthcare). For CTA, retrospectively gated scanning of the thorax and the abdomen was performed; ECG dose modulation was used.
The scanning length and time as well as the dose length product (DLP) of the CTA were measured, and the total effective radiation dose was calculated by multiplying the DLP times a conversion factor (0.015 mSv/cGy/cm) as previously suggested. 16 The dataset of the contrast-enhanced scan of the heart was reconstructed at 70, 75, and 80% of the RR interval. 5 For patients who showed suboptimal image quality on mid-diastolic phases due to variable or high heart rates, additional reconstruction of images for systolic phases (35, 40, and 45% of the RR interval) was performed. All images were transferred to an external workstation (AW-4.5, GE-Healthcare) for post-processing analysis. Ultra-low contrast 64-slice CTA before TAVI
CM injection protocols
A non-ionic, iso-osmolar contrast agent with an iodine concentration of 320 mg/mL (Iodixanol 320, GE-Healthcare), prepared at 378C, was injected into an antecubital vein through a 20-or 18-gauge catheter using a dual-shot injector (Nemoto Kyorindo, Tokio, Japan). All enhanced CT acquisitions were performed using our dedicated multiphasic injection protocol. The total amount of CM was tailored to the patient's BMI and was administered with five boluses at different flow rates, resulting in a total of 40 mL (12.8 . No saline flush was used after CM injection for the unfeasibility of adding a sixth bolus, due to injector's software limitations.
The key contrast material injection parameters of our protocol are summarized in Figures 1 and 2 . An example of the ECG-assisted CTA acquisition process in real time is Supplementary data online, Video S1 and Figure S1 , Video S2 and Figure S2 .
Low injection rates (from 2 to 3 mL/s) were set for the first two boluses, to determine the contrast bolus arrival time, serving as a kind of bolus test injection. The third phase of the injection consisted of a small volume (10 or 15 mL) of contrast agent injected at a rapid delivery rate (5 mL/s). The injection rate needed to be increased to compensate for the small-injected volume and the low iodine concentration (320 mgI/mL) of the CM used, to build up annulus and coronary artery opacification. The last two phases consisted of two small volumes of contrast agent (10 and 15 mL), with decelerating delivery rates from 3.5 to 2.5 mL/s to exploit the cumulative effects of bolus broadening and achieve homogeneous prolonged vascular opacification. The resulting overall injection duration for the two protocols was 13 and 17 s, respectively, while CTA acquisition time for TAVI examinations was 25 s. Bolus tracking was 
CT data analysis Feasibility: vessel attenuation and image quality
Intraluminal attenuation and image noise in Hounsfield Units (HU) were assessed as objective image parameters by a single reader. Arterial opacification was measured at six different positions in the thoraco-abdominal aorta and along the ilio-femoral vessels using circular regions of interest (ROIs) drawn as large as possible, carefully avoiding calcifications, plaques, and stenosis. Image noise was calculated as the standard deviation (SD) of the attenuation in the ROIs. 17 The diagnostic quality and interpretability of both aortic root and aorto-iliac CTA images were graded by two experienced radiologists using the following semi-quantitative 4-point scale: 1, bad (insufficient opacification or severe motion artefacts); 2, poor (inhomogeneous enhancement with markedly blurred vessel edges, pronounced motion artefacts); 3, adequate (homogeneous enhancement with moderately blurred vessels edges, only minor motion artefacts); and 4, good (homogeneous enhancement with good visibility of the anatomic details, no motion artefacts). Images classified as good and adequate were considered evaluable/diagnostic. Disagreements in data analysis between the two observers were resolved by consensus reading.
Sizing: aortic annulus and peripheral artery evaluation
For the evaluation of the aortic root, a dedicated post-processing software (CardIQ X-Press, GE Healthcare) was used. Measurements (minimum and maximum diameters, perimeter, and area) of the annulus were taken in an orthogonal plane at the level of the basal attachments of all three aortic valve cusps using the reconstructed double oblique transverse view ( Figure 3 ). The coronary ostia height was also calculated. Ultra-low contrast 64-slice CTA before TAVI package, GE Healthcare). The presence of calcifications at left ventricle outflow tract (LVOT), cusps, and commissures was also noted. For assessment of the aorto-iliac vasculature, curved planar reformatted and 3D volume-rendered images were reconstructed (Vessels Analysis, CardioQ3 package, GE Healthcare). Minimum vessel diameters along the entire course of the ilio-femoral system were assessed. At our institution, the relevant minimal vessel diameter required was set at 6 mm. Calcifications of vessel segments were scored using a 4-point scale: 0, no calcified plaque; 1, mildly calcified with solitary punctiform plaques; 2, moderate calcifications covering ,50% of the vessel's length; and 3, severe calcification covering .50% of the vessel's length, or circumferential wall calcification. The presence of severe tortuosity was also noted. 18 
TAVI procedure and clinical outcomes
Eligibility for TAVI and amenability to transfemoral access were then evaluated by a multidisciplinary group (heart team) in consensus.
TAVI devices used include the balloon-expandable Edwards Sapien valve (Edwards Lifesciences, Irvine, CA, USA), the self-expandable CoreValve ReValving system (Medtronic, Minneapolis, MN, USA), and the Direct Flow Medical Transcatheter Aortic Valve (Direct Flow Medical, Santa Rosa, CA, USA). Valve of choice was at the discretion of the operator according to the patient's anatomy. Transcatheter valve sizing was based on CT-derived annular measurement taking into account there are numerous factors such as LVOT calcification, leaflet calcification and symmetry, sino-tubular junction diameter and calcification, coronary height, and sinus of valsalva diameter. As regards to annular dimensions, our sizing protocol can be summarized as follows: (i) Edwards Balloon-expandable valves: systolic area with 5 -10% oversizing; (ii) CoreValve: systolic perimeter and perimeter-derived diameter with 10 -20% oversizing; and (iii) Direct Flow: diastolic perimeterderived diameter with 1 : 1 sizing and minimal oversizing.
Procedural success was defined by the absence of peri-procedural mortality, correct positioning of a single prosthetic valve at the ideal anatomical location, and prosthesis performance (no prosthesis-patient mismatch, mean aortic valve gradient ,20 mmHg or peak velocity ,3 m/s and absence of significant regurgitation). Clinical outcomes after TAVI were assessed according to the valvular academic research consortium (VARC-2) criteria at 30 days and 1 year. 22 Early safety at 30 days was defined by the incidence of all-cause mortality, stroke, life-threatening bleeding, AKI, coronary artery obstruction requiring intervention, major vascular complications, and valve-related dysfunction requiring a repeat procedure. Clinical efficacy at 1 year was defined by the incidence of all-cause mortality, stroke, hospitalizations for valve-related symptoms or worsening congestive heart failure, NYHA Class III or IV, and valve-related dysfunction (mean aortic valve gradient .20 mmHg, and/or moderate or severe prosthetic valve regurgitation).
Statistical analysis
All statistical analyses were performed using SPSS version 17.0 (SPSS) ) was recorded for all examinations and the effective radiation exposure estimated in mSv.
Results
Baseline characteristics of the study population are listed in Table 2 . CTA was successfully performed in all patients. The mean heart rate was 72.5 + 15.1 bpm (range: 39 -116 bpm), and the mean heart rate variability was 14.7 + 12.3 bpm (range: 1 -47 bpm). One hundred and thirteen patients (69.8%) showed sinus rhythm Figure 6 Representative reconstructed images for assessment of ilio-femoral vessels diameters, tortuosity, and wall calcifications.
Eighty-four-year-old woman candidate for TAVI (BMI 25.1 kg/m 2 , heart rate 74 + 13 bpm, EF 50%). Volume-rendered images (A and B) and transverse views of curved planar reconstructions at different iliac axis levels and the corresponding diameters (C and D). The patient was accepted for TAVI given the adequate arterial size, the paucity of vessel tortuosity, and the presence of moderate calcifications. during CTA acquisition, while 49 patients (30.2%) had arrhythmias, of which 40 (24.7%) were in atrial fibrillation (AF) and 9 (5.5%) had supraventricular or ventricular ectopic beats. In 59 patients (36.4%), additional end-systolic image reconstructions were performed because of suboptimal image quality on mid-diastolic phases.
The mean scan length was 63.4 + 2.0 cm (range: 59.2 -66.1 cm); the mean scan time was 25 + 2 s (range: 22 -27 s). The mean DLP for thoraco-abdominal CTA was 1346.4 + 307 mGy/cm, resulting in an estimated mean effective radiation dose of 20.2 + 4.6 mSv (range: 16.3-27.8 mSv).
Feasibility: vessel attenuation and image quality
Mean vessel attenuation was 398.1 + 87.1 HU (range: 289.1 -596.7 HU) in the ascending aorta and 328.6 + 99.3 HU (range: 201.6 -580.6 HU) in the iliac arteries, so that both the aortic annulus and the vascular access could always be evaluated (Figure 4) . The mean image noise was 21.1 + 7 HU (range: 10.9 -36.8 HU) in the ascending aorta, 24.2 + 6.6 (range: 14.1 -36.8 HU) in the right external iliac artery, and 25.2 + 7.2 HU (range: 15.1 -47.4 HU) in the left external iliac artery.
For the aortic root, image quality was independently scored to be diagnostic by both readers in all cases; it was rated as being 'good' in 109 scans (67.3%). The mean image quality score at this level was 3.7 + 0.5 (range: 3 -4).
Also for the aorto-iliac vasculature, diagnostic image quality was achieved in all patients. The mean image quality score was 3.5 + 0.5 (range: 3-4) at the level of external iliac arteries with 89 scans (54.9%) ranked as Grade 4, and 73 scans (45.1%) as Grade 3, respectively.
Representative images and reconstructions are displayed in Figures 5 and 6 .
Sizing: aortic annulus and peripheral artery evaluation
Aortic root dimension, vessel diameters, the presence and extent of aortic valve, and vessel wall calcifications could be evaluated in all patients. CTA annulus and ilio-femoral vasculature characteristics are listed in Table 3 .
Most of the aortic valves (156, 96.3%) were tricuspid and heavily calcified while six valves (3.7%) were bicuspid. The mean maximum and minimum diameters of the aortic annulus were 26 + 3 mm (range: 20-33 mm) and 22 + 3 mm (range: 16-28 mm), respectively; the mean perimeter was 77.0 + 7.1 mm (range: 65-93 mm). The mean coronary ostia heights were 12.8 + 2.8 mm (range: 9-17 mm) for the left main and 14.9 + 3.1 (range: 8-19 mm) for the right coronary artery, respectively; no patients were considered unsuitable for current TAVI devices.
The mean minimum diameter of the ilio-femoral vessels was 6.6 + 1.2 mm (range: 3.8 -9.3 mm). In 29 patients (17.9%), the minimum diameter of both sides of the ilio-femoral arteries was below 6 mm or severe calcifications and tortuosity combined with a borderline vessel diameter were present. Thus, 27 patients (16.7%) were deemed non-amenable to transfemoral access, while 2 patients (1.2%) were judged to be amenable to transfemoral access after a preceding intervention.
TAVI procedure and results
After CTA examination, a total of 137 patients (84.6%) underwent TAVI. Of these, 120 (87.6%) via transfemoral, 8 (5.8%) via transaxillary, 3 (2.2%) via transapical approach, and 6 (4.4%) via transaortic approach.
According to the ESC guidelines, 23 The overall procedural success rate was 90.5% (n ¼ 124). No intraprocedural death occurred. Clinical outcomes at 30 days are reported in Table 4 , and VARC-2 composite end points are shown in Table 5 .
Discussion
CTA has gained an increasingly important role in patient screening protocols before TAVI and is of fundamental importance to provide a thorough assessment of aortic annulus and vascular access site suitability, to prevent vascular complications and optimize procedural outcome. Indeed, increasing data have demonstrated that CTA sizing is associated with a reduced incidence of paravalvular leak.
5,8
The high volumes of iodinated CM injected during the examination represent the main limitation of CTA with a dose-dependent association with contrast-induced nephropathy.
24,25
The total amount of CM for CTA imaging of patients scheduled for TAVI is reported to range from 120 to 140 mL, 5,18 -21 while the average contrast injected during a standard TAVI procedure is around 100-300 mL. 26, 27 Given the repeat exposure of these frail Results reported as n (%).
patients to contrast dye during the TAVI work-up and procedure, a reduction in CM dose is of paramount importance. Two recent studies showed the feasibility of ultra-low-dose CM injection protocols of only 20 or 50 mL using 128-detector-row dual-source CT with high-pitch spiral scan mode. 28, 29 The authors demonstrated that dual-source CT with a minimized volume of CM can be used to provide acceptable image quality of the entire aorta in TAVI candidates. However, only a few specialized institutions can currently take advantage of the improved scan speed of the latest generations of CT scanners, including dual-source CT or wide-area detectors; while 64-slice CT remains the most frequently employed technology for clinical use in everyday practice. Using conventional 64-slice CT systems, the optimization of the contrast protocol is certainly more complex and technically challenging, but still possible.
In our study, the feasibility of an ultra-low-dose CM injection protocol for 64-slice CTA was investigated. We designed two different injection protocols of 40 and 55 mL of CM for the two classes of selected BMI (,22 and 22-29 kg/m 2 , respectively), demonstrating that an adequate and homogeneous opacification of target vascular territories is achievable. With our protocol, an overall moderate arterial opacification greater of 200 HU was guaranteed throughout the entire aorta in all cases, so that both the aortic root and vascular access anatomy could be evaluated. Thus, vascular attenuation was sufficient to assess patient eligibility and to target the proper TAVI approach in all cases, despite the low dose of injected CM.
The resulting overall procedural success rate was high and the clinical outcomes after TAVI were satisfactory. These results have been made possible by exploiting the characteristics of our patient population: elderly, often debilitated patients with low mean values of BMI and ejection fraction (EF). Several previous reports demonstrated that BMI and EF are the key physiological parameters affecting CM distribution and are inversely related to the degree of arterial enhancement. 30 Particularly, the mean BMI of our patient population was 23.7 kg/cm 2 , and 60 patients (37%) had a BMI of ,22 kg/m 2 , while the mean EF was 48% and 46 patients (28.4%) had a EF ,40%. This allowed us to increase the magnitude of arterial enhancement and obtain stronger prolonged contrast.
Limitations
Our study has some limitations. First, a post-procedural creatinine was not measured and the incidence of contrast-induced nephropathy after CTA could not be evaluated. However, given the minimal additional contrast dye burden of up to 55 mL, a post-procedural worsening of renal function could be expected to be less severe.
Our aim was to demonstrate the effectiveness of our protocol in terms of pre-procedural diagnosis and the implications for prosthesis sizing and implantation. Given the feasibility of our protocol, its impact on renal function should be further evaluated with randomized studies with control groups. Second, selection of the BMI-adapted contrast protocol was arbitrary, the study was retrospective and we limited enrolment to patients with a BMI inferior to 29 kg/m 2 to overcome the variability in vessel opacification due to CM dilution depending on the blood volume of the individual. However, in our experience, only 17.8% of patients who underwent pre-TAVI CTA were excluded because of BMI. As already mentioned, patients scheduled for TAVI are usually elderly and critically ill patients, with low mean values of BMI. Thus, the findings of the present study seem adequate to document that our low-dose injection protocol is feasible. Further prospective and randomized studies are needed to assess the applicability of our results to each class of BMI. Finally, the mean effective radiation dose was high (20.2 mSv), because the patients were imaged with a retrospectively gated CT aortic angiogram protocol. It was not possible to perform a helical non-gated scanning of the abdomen during the same contrast bolus as the preceding delay of 6 s, necessary to change the scanning mode, was too high and would have yield inferior diagnostic images. However, radiation is of minor relevance in the elderly and critically ill population studied and it was not our major concern.
In conclusion, our study shows the feasibility of an ultra-low-dose CM injection protocol for 64-slice CT of TAVI candidates. The most essential information for planning a TAVI procedure can be assessed in a single, non-invasive, screening examination with a dramatic reduction of injected CM dose.
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